San Francisco-based Meissa Vaccines has announced it is intiating pre-clinical studies of its live attenuated vaccine (LAV) against SARS-CoV-2, the virus which causes Covid-19.
The vaccine candidate, MV-014-210, is a intranasal, adjuvant free vaccine, which was build on Meissa’s respiratory syncytial virus (RSV) vaccine platform.
Meissa also announced it has completed its pre-investigational new drug application with the US Food and Drug Administration.
The company’s CEO and co-founder Martin Moore noted: “The Covid-19 vaccine pipeline is dominated by non-replicating vaccines, while live attenuated vaccines are known to induce long-lasting immunity after a single adjuvant-free dose, presenting an economical and effective solution to this global pandemic.
“A single dose of MV-014-210 may be sufficient to generate immunity against SARS-CoV-2. Furthermore, building our Covid-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.”
